Target Price | $250.19 |
Price | $158.71 |
Potential | 57.64% |
Number of Estimates | 27 |
27 Analysts have issued a price target Biogen 2025 . The average Biogen target price is $250.19. This is 57.64% higher than the current stock price. The highest price target is $342.00 115.49% , the lowest is $180.00 13.41% . | |
A rating was issued by 38 analysts: 23 Analysts recommend Biogen to buy, 15 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2025 of 57.64% . Most analysts recommend the Biogen stock at Purchase. |
30 Analysts have issued a sales forecast Biogen 2024 . The average Biogen sales estimate is $9.6b . This is 4.45% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.7b 5.61% , the lowest is $9.5b 2.48% .
This results in the following potential growth metrics:
2023 | $9.4b | 0.17% |
---|---|---|
2024 | $9.6b | 2.36% |
2025 | $9.5b | 1.37% |
2026 | $9.7b | 1.91% |
2027 | $10.0b | 3.65% |
2028 | $10.2b | 1.73% |
9 Analysts have issued an Biogen EBITDA forecast 2024. The average Biogen EBITDA estimate is $3.3b . This is 21.48% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.9b 43.63% , the lowest is $2.7b 1.83% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $2.1b | 23.87% |
---|---|---|
2024 | $3.3b | 57.02% |
2025 | $3.5b | 4.19% |
2026 | $3.5b | 0.85% |
2027 | $4.3b | 22.50% |
2028 | $4.9b | 14.86% |
2023 | 22.58% | 23.74% |
---|---|---|
2024 | 34.63% | 53.38% |
2025 | 36.58% | 5.63% |
2026 | 36.20% | 1.04% |
2027 | 42.79% | 18.20% |
2028 | 48.31% | 12.90% |
12 Biogen Analysts have issued a net profit forecast 2024. The average Biogen net profit estimate is $1.8b . This is 11.42% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.4b 47.61% , the lowest is $1.6b 2.53% .
This results in the following potential growth metrics and future Net Margins:
2023 | $1.2b | 61.81% |
---|---|---|
2024 | $1.8b | 54.75% |
2025 | $2.1b | 16.46% |
2026 | $2.5b | 18.53% |
2027 | $2.8b | 14.77% |
2028 | $3.2b | 10.74% |
2023 | 12.33% | 61.74% |
---|---|---|
2024 | 18.64% | 51.16% |
2025 | 22.01% | 18.08% |
2026 | 25.60% | 16.31% |
2027 | 28.35% | 10.74% |
2028 | 30.86% | 8.85% |
12 Analysts have issued a Biogen forecast for earnings per share. The average Biogen <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $12.33 . This is 11.38% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $16.34 47.61% , the lowest is $10.79 2.53% .
This results in the following potential growth metrics and future valuations:
2023 | $7.97 | 61.81% |
---|---|---|
2024 | $12.33 | 54.71% |
2025 | $14.36 | 16.46% |
2026 | $17.03 | 18.59% |
2027 | $19.54 | 14.74% |
2028 | $21.64 | 10.75% |
Current | 14.34 | 37.81% |
---|---|---|
2024 | 12.87 | 10.25% |
2025 | 11.05 | 14.14% |
2026 | 9.32 | 15.66% |
2027 | 8.12 | 12.88% |
2028 | 7.33 | 9.73% |
Based on analysts' sales estimates for 2024, the Biogen stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 2.91 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 2.40 .
This results in the following potential growth metrics and future valuations:
Current | 3.04 | 25.12% |
---|---|---|
2024 | 2.91 | 4.18% |
2025 | 2.95 | 1.39% |
2026 | 2.90 | 1.87% |
2027 | 2.80 | 3.52% |
2028 | 2.75 | 1.70% |
Current | 2.51 | 28.34% |
---|---|---|
2024 | 2.40 | 4.26% |
2025 | 2.43 | 1.39% |
2026 | 2.39 | 1.87% |
2027 | 2.30 | 3.52% |
2028 | 2.26 | 1.70% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.